To provide managed care pharmacists, VA pharmacists, and Department of Defense pharmacists with up-to-date information regarding their role in the treatment of patients with colorectal cancer.
This activity is designed for managed care pharmacists, VA pharmacists, and Department of Defense pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:
- Discuss the safety and efficacy of currently available and emerging treatments for colorectal cancer (CRC).
- Compose appropriate strategies for managing side effects of current CRC therapies.
- Integrate knowledge of the efficacy and safety of current and emerging treatments into strategic therapy regimens for patients.
- Consider the impacts of therapies for CRC on the patient, the caregiving facility, and the payer, including clinical benefit and pharmacoeconomic considerations.
- Evaluate the benefits of combination therapy regimens for your patients.
- Describe obstacles to patient compliance with chemotherapeutic regimens and recommend supportive care strategies to optimize treatment.
- Explain how changes in reimbursement affect the selection of agents and the setting for delivery of care.
The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.
CREDIT DESIGNATION STATEMENT
This program is approved for 2 hours of credit (0.2 CEUs) and is sponsored by the University of Tennessee College of Pharmacy, which is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE Program #064-000-07-214-H01-P.
This continuing education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.
The estimated time to complete this educational activity: 2 hours.
Release date: October 15, 2007. Expiration date: October 15, 2009.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
This program is supported by an educational grant from Amgen, Inc.